EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltag025 ↗

Kurz gefasst

Korrektur in der Zeitschrift Immunotherapy Advances, online erschienen am 30.10.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2025). Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag025

Vancouver

Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag025

BibTeX
@article{euvimed2025,
  title = {Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltag025}
}
Kostenlos starten →